High throughput electrophysiology: New perspectives for ion channel drug discovery

Receptors and Channels

Volumn 9, Issue 1, 2003, Pages 3-12

  Willumsen, Niels J ^a,b   Bech, Morten ^a   Olesen, Søren Peter ^c   Jensen, Bo Skaaning ^d   Korsgaard, Mads P G ^d   Christophersen, Palle ^d  

^a Sophion Bioscience A/S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d NONE

Author keywords

Channelopathies; Drug discovery; HTS electrophysiology; Patch clamp

Indexed keywords

AMIODARONE; AMLODIPINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; DILTIAZEM; DISOPYRAMIDE; FELODIPINE; GLIBENCLAMIDE; ION CHANNEL; LACIDIPINE; LAMOTRIGINE; LIDOCAINE; LORAZEPAM; MEXILETINE; MUSCLE RELAXANT AGENT; NIFEDIPINE; NITRAZEPAM; PHENYTOIN; POTASSIUM CHANNEL BLOCKING AGENT; QUINIDINE; SILICON; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL;

ACCURACY; ANALYTIC METHOD; BIOASSAY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; ELECTROPHYSIOLOGY; EPILEPSY; HEART ARRHYTHMIA; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATCH CLAMP; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELIABILITY; REVIEW; SCREENING TEST; SENSITIVITY ANALYSIS;

ANIMALS; DRUG DESIGN; HUMANS; ION CHANNELS; MODELS, BIOLOGICAL; MUTATION; PATCH-CLAMP TECHNIQUES; TIME FACTORS;

EID: 0037236477     PISSN: 10606823     EISSN: None     Source Type: Journal    
DOI: 10.1080/10606820308259     Document Type: Review

References (15)

1. Ashcroft, F. M. 2000. Ion Channels and Disease. Academic Press, New York, 481 pp.
2. Asmild, M., Oswald, N., Krzywkowski, K., Friis, S., Jacobsen, R. B., Reuter, D., Taboryski, R., Kutchinsky, J., Vestergaard, R. K., Schrøder, R. L., Sørensen, C. B., Bech, M., Korsgaard, M. P. G., and Willumsen, N. J. 2003. Receptors and Channels 9:49-57.
3. Bargmann, C. 1998. Science 282(5396):2028-2033.
4. Committee for Proprietary Medicinal Products. 1997. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. CPMP/986/96.
5. Hamill, O. P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F. J. 1981. Pflügers Arch. 391:85-100.
6. Harte, R., and Ouzounis, C. A. 2002. FEBS Lett. 514(2-3):129-134.
7. Hille, B. 2001. Ion channels of excitacle membranes 3 ed. Sinauer Associates.
8. Hodgkin, A. L., and Huxley, A. F. 1952. J. Physiol. 117:500-544.
9. Lehmann-Horn, F., and Jurkat-Rott, K. 1999. Physiol. Rev. 79:1317-1372.
10. Mitcheson, J. S., Chen, J., Culberson, C., and Sanguinetti, M. C. 2000. Proc. Natl. Acad. Sci. USA 97:12329-12333.
11. Neher, E., and Sakmann, B. 1976. Nature 260:799-802.
12. Owen, D., and Silverthorne, A. 2002. Drug Discovery World, Spring 2002.
13. Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., Drumm, M. L., Ianuzzi, M. C., Collins, F. S., and Tsui, L.-C. 1989. Science 245:1066-1073.
14. Venter, J. C., et al. 2001. Science 291:1304-1351.
15. Xu, J., Wang, X., Ensign, B., Li, M., Wu, L., Guia, A., and Xu, J. 2001. Drug Discovery Today 6:1278-1287.